LabCorp Gets Analyst Boost on MCO Rolls, Impending Dx-Volume Boost

"Our confidence in our near-term outlook [for the clinical-lab industry] has improved, including improving [managed-care] enrollment trends … and growth within [LabCorp's] drugs-of-abuse testing.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.